Skip to main
CLGN
CLGN logo

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd has strengthened its position in the regenerative medicine and aesthetics sectors, which enhances its long-term growth potential. The company's partnership with AbbVie has resulted in $24 million of milestone payments, indicating strong commercial viability for its rhCollagen technology and reinforcing corporate confidence in its applications. Additionally, the recent patent securing CollPlant's intellectual property until 2039 consolidates its competitive edge in the aesthetics market and supports ongoing advancements toward human trials.

Bears say

CollPlant Biotechnologies Ltd faces a challenging financial landscape characterized by reliance on a limited number of revenue streams, primarily from collaborations and niche product sales in the regenerative medicine and aesthetics sectors. The company's dependence on advanced technologies for 3D bioprinting of tissues and organs may hinder its ability to scale effectively due to high entry barriers and increased competition within the biotechnology field. Furthermore, the fluctuating market demand for rhCollagen related products and the ongoing need for significant investment in research and development could impede consistent revenue growth and overall financial stability.

CLGN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 4 analysts, CLGN has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.